. .

. . *, ,
. . **
* ,
** . . . . . ,

. . 1015 -, . , . , . . - . , , . , , , . , , , [1]. ; ; ; ; [2].

/ , , , .

/ . , , , - . , . , , , [3].

. [4], 33 , . , 206 , . 206 9 , , . , . Jadad, , , /: ; ; [5]. , [6].

. , (). , () .

, , 3- [79]:

1) , , , , , ;
2) ;
3) , , .

, .

, D, [10]. , , , , [11].

, : ; ; ; . . , . , , . , , , [12].

(Bayesian mixed-treatment comparisons model) [13].

: . , , , , , . . (, , ) , , , . , , . , . () . () , , , , , [14]. , , .

[15], [1618], , [19], , [2022]. , [13], [23].

PubMed 7 , 3 I. Rotta [18, 21, 23] .

I. Rotta . 4400 , [23]. 65 . . .

.

. . . , 21 5627 [22]. .

I. Rotta . . , (), , (, , ), , , . , , . .

M. El-Gohary . 364 , 129 18 086 [2425]. ( ) . , 24 , 1 6 . , . . , . . . . , , , , , .

, , , , . .

20152016 . Stein L. F. Gold, T. Vlahovic . , (moccasin tinea pedis) [2627]. 1174 , 500 , . (1,7% 0,9% ), 6 66% 8% , 19,2% 0,9% .

- [28].

, , [29].

[30], , , , [31], , , [32].

( ) . () , . , , . , .

, , , .

1. LAbbé K. A., Detsky A. S., ORourke K. Meta-analysis in clinical research // Ann Intern Med. 1987; 107 (2): 224233.
2. Furberg C. D., Morgan T. M. Lessons from overviews of cardiovascular trials // Stat Med. 1987, Apr-May; 6 (3): 295306.
3. Egger M., Smith G. D., Sterne J. A. Meta-analysis: is moving the goal post the answer? // Lancet. 1998; 351 (9114): 1517.
4. Verhagen A. P., de Vet H. C., de Bie R. A., Kessels A G., Boers M., Bouter L. M., Knipschild P. G. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus // J Clin Epidemiol. 1998; 51 (12): 12351241.
5. Olivo S., Macedo L. G., Gadotti I. C., Fuentes J., Stanton T., Magee D. J. Scales to Assess the Quality of Randomized Controlled Trials: A Systematic Review // Physical therapy. 2008. 88 (2): 156175.
6. Jüni P., Witschi A., Bloch R., Egger M. The hazards of scoring the quality of clinical trials for meta-analysis // JAMA. 1999; 282 (11): 10541060.
7. Sidbury R., Davis D. M., Cohen D. E., Cordoro K. M., Berger T. G., Bergman J. N., Chamlin S. L., Cooper K. D., Feldman S. R., Hanifin J. M., Krol A., Margolis D. J., Paller A. S., Schwarzenberger K., Silverman R. A., Simpson E. L., Tom W. L., Williams H. C., Elmets C. A., Block J., Harrod C. G., Begolka W. S., Eichenfield L. F. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents // J Am Acad Dermatol. 2014; 71 (2): 327249.
8. Galli E., Neri I., Ricci G., Baldo E., Barone M., Belloni Fortina A., Bernardini R., Berti I., Caffarelli C., Calamelli E., Capra L., Carello R., Cipriani F., Comberiati P., Diociaiuti A., El Hachem M., Fontana E., Gruber M., Haddock E., Maiello N., Meglio P., Patrizi A., Peroni D., Scarponi D., Wielander I., Eichenfield L. F. Consensus Conference on Clinical Management of pediatric Atopic Dermatitis // Ital J Pediatr. 2016; 42 (1): 26.
9. Katayama I., Kohno Y., Akiyama K., Aihara M., Kondo N., Saeki H., Shoji S., Yamada H., Nakamura K. Japanese Society of Allergology. Japanese Guideline for Atopic Dermatitis 2014 // Allergol Int. 2014; 63 (3): 377398.
10. (), 20052012 .
11. Berlin J. A., Rennie D. Measuring the quality of trials: the quality of quality scales // JAMA. 1999; 282 (11): 10831085.
12. . . . .: , 2001. 362 .
13. Hong H., Chu H., Zhang J., Carlin B. P. A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons // Res Synth Methods. 2016, Mar; 7 (1): 622.
14. Ryder N. S. Specific inhibition of fungal sterol biosynthesis by SF 86327, a new allylamine antimycotic agent // Antimicrob Agents Chemother. 1985, Feb; 27 (2): 252256.
15. Stein Gold L. F., Parish L. C., Vlahovic T., Plaum S., Kircik L., Fleischer A. B. Jr., Verma A., Olayinka B., Hardas B. Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials // J Drugs Dermatol. 2013, Aug; 12 (8): 911918.
16. Hart R., Bell-Syer S. E., Crawford F., Torgerson D. J., Young P., Russell I. Systematic review of topical treatments for fungal infections of the skin and nails of the feet // BMJ. 1999, 10; 319 (7202): 7982.
17. Apasrawirote W., Udompataikul M, Rattanamongkolgul S. Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis // J Med Assoc Thai. 2011, Jun; 94 (6): 756760.
18. Rotta I., Sanchez A., Gonçalves P. R., Otuki M. F., Correr C. J. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review // Br J Dermatol. 2012, May; 166 (5): 927933.
19. Fedorowicz Z., van Zuuren E. J. Efficacy of topical antifungal agents in the treatment of dermatophytosis: an incomplete meta-analysis // JAMA Dermatol. 2013, Oct; 149 (10): 12431244.
20. Korting H. C., Kiencke P., Nelles S., Rychlik R. Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis // Am J Clin Dermatol. 2007; 8 (6): 357364.
21. Rotta I., Otuki M. F., Sanches A. C., Correr C. J. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis // Rev Assoc Med Bras. 2012, May-Jun; 58 (3): 308318.
22. ., . . // . 2015, . 02, 4, . 4653.
23. Rotta I., Ziegelmann P. K., Otuki M. F., Riveros B. S., Bernardo N. L., Correr C. J. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments // JAMA Dermatol. 2013; 149 (3): 341349.
24. El-Gohary M., van Zuuren E. J., Fedorowicz Z., Burgess H., Doney L., Stuart B., Moore M., Little P. Topical antifungal treatments for tinea cruris and tinea corporis // Cochrane Database Syst Rev. 2014; 8: CD009992.
25. Van Zuuren E. J., Fedorowicz Z., El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review // Br J Dermatol. 2015; 172 (3): 616641.
26. Vlahovic T. C. The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis // J Drugs Dermatol. 2016; 15 (2): s5659.
27. Stein Gold L. F., Vlahovic T., Verma A., Olayinka B., Fleischer A. B. Jr. Naftifine Hydrochloride Gel 2%: An Effective Topical Treatment for Moccasin-Type Tinea Pedis // J Drugs Dermatol. 2015; 14 (10): 11381144.
28. Verma A., Olayinka B., Fleischer A. B. Jr. An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis // J Drugs Dermatol. 2015; 14 (7): 686691.
29. Kircik L. H., Onumah N. Use of naftifine hydrochloride 2% cream and 39% urea cream in the treatment of tinea pedis complicated by hyperkeratosis // J Drugs Dermatol. 2014; 13 (2): 162165.
30. Routt E. T., Jim S. C., Zeichner J. A., Kircik L. H. What is new in fungal pharmacotherapeutics? // J Drugs Dermatol. 2014; 13 (4): 391395.
31. Schmeel L. C., Schmeel F. C., Blaum-Feder S., Schmidt-Wolf I. G. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma // Anticancer Res. 2015; 35 (11): 59215926.
32. Erdal M. S., Özhan G., Mat M. C., Özsoy Y., Güngör S. Colloidal nanocarriers for the enhanced cutaneous delivery of naftifine: characterization studies and in vitro and in vivo evaluations // Int J Nanomedicine. 2016; 11: 10271037.